Feb

2012

Ember Therapeutics, Inc.: Series A $34.1M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, X - Therapeutic Platform, XX - MA

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

Jul

2011

GenKyoTex, SA: Series C $20.8M

Posted in I - Series C, Q - 2Q11, R - INTERNATIONAL, X - Diabetes

GenKyoTex (Switzerland) a clinical-stage pharmaceutical company focused on the treatment of complications of diabetes including diabetic nephropathy, closed a $20.8M Series C financing. Participants include Edmond de Rothschild Investment Partners, Vesalius Biocapital, MP Healthcare Venture Management and Specialized European Fund for Therapeutic Innovation.

Sep

2010

Rhythm Pharmaceuticals, Inc: Series A $19M

Posted in I - Series A, Q - 3Q10, R - NORTH EAST, X - Diabetes, X - GI, X - Obesity, XX - MA

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage small peptide company focused on diabetes, obesity and GI disorders, closed a $19M Series A financing, bringing the total round to $40M. Participants include MPM Capital, New Enterprise Associates and Third Rock Ventures.

Aug

2010

Poxel, SA: Series A $20.3M

Posted in I - Series A, Q - 3Q10, R - INTERNATIONAL, X - Diabetes, X - Metabolism

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Apr

2010

Intercept Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 1Q10, R - NORTH EAST, X - Cirrhosis, X - Diabetes, X - FXR, XX - NY

Intercept Pharmaceuticals (New York, NY) a clinical-stage small molecule drug company focused on modulation of bile acid signaling in primary biliary cirrhosis and type II diabetics with fatty acid liver disease, closed a $25M Series B financing. Participants include Genextra.

Mar

2010

NGM Biopharmaceuticals, Inc.: Series B $51M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Diabetes, X - Metabolism, X - Obesity, XX - CA

NGM Biopharmaceuticals (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on diabetes, obesity and muscle wasting, closed a $51M Series B financing. Participants include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.

Mar

2010

Rhythm Pharmaceuticals, Inc.: Series A $10M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Diabetes, X - GI, X - Metabolism, X - Obesity, XX - MA

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

Oct

2009

Alimera Sciences, Inc.: Series C $5M

Posted in I - Series C, Q - 3Q09, R - SOUTH EAST, X - Diabetes, X - Opthalmology, XX - GA

Almeria Sciences (Atlanta, GA) a clinical-stage biopharma company focused on ophthalmic disease and treatment of diabetic macular edema, closed a $5M Series C, bringing the total round to $35. Participants have included Polaris Venture Partners, Intersouth Partners, Venrock Associates, Domain Associates and Scale Venture Partners.

Jul

2009

Allostera Pharma, Inc.: Series C $15.4M

Posted in I - Series C, Q - 3Q09, R - INTERNATIONAL, X - Autoimmune, X - Diabetes, X - Gout, X - Psoriatic Arthritis

Allostera Pharma (Canada) a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes, closed a $15.4M Series C financing. Participants include iNovia Capital, Genesys Capital, BDC Venture Capital and GO Capital.

Jun

2009

Versartis, Inc.: Series A $11M

Posted in I - Series A, Q - 2Q09, R - WEST, X - Diabetes, X - Endocrinology, X - Growth Deficiency, X - Metabolism, XX - CA

Versartis (Redwood City, CA) a preclinical-stage large molecule company focused on diabetes and growth hormone deficiency, closed an $11M Series A financing. Participants include Index Ventures.

Jun

2009

Avid Radiopharmaceuticals, Inc.: Series D $34.5M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Alzheimer's, X - Dementia, X - Diabetes, X - Imaging, X - Parkinson's, XX - PA

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.

Jun

2009

Metabolic Solutions Development Co.: Series B $9.3M

Posted in I - Series B, Q - 2Q09, R - MID WEST, X - Diabetes, XX - MI

Metabolic Solutions Development (Kalamazoo, MI) a clinical-stage biopharmaceutical company focused on Type II diabetes, closed a $9.5M Series B financing. Participants include Southwest Michigan First Life Science Fund and Hopen Therapeutics.

Jun

2009

NovImmune, SA: Series C $54.8M

Posted in I - Series C, Q - 2Q09, R - INTERNATIONAL, X - Antibody, X - Diabetes, X - Immunology, X - Inflammation

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on therapeutic monoclonal antibodies for inflammatory diseases and immune related disorders, closed a $54.8M series C financing. Participants include BZ Bank Aktiengesellschaft.

« Previous Entries

to top of page...